What a buyer sees
PRINCIPLE HEALTHCARE LIMITED
Manufacture of basic pharmaceutical products · Leeds · 04283476
16staff · FY2025
25years trading
—oldest owner on file
£1.4Mcash at bank
Your turnover is on public record
filed£18Mfor the year to 2025
Unusual at this size, and it works in your favour: a buyer is reading your number rather than guessing at one.
What your filings show moving
Staff16
202114 → 162025
Cash at bank£1.4M
2021£774k → £1.4M2025
How you sit in your trade
slowest tenth typical fastest tenth youSales per employee£1,153,431above almost all
£75,818£268,200£906,093
Debtor daysdays38in the middle half
225592
Creditor daysdays42
113064
Stock daysdays76in the middle half
1049126
Each spread is companies in the same trade and size that did publish a turnover. Creditor days are shown but not marked: neither end of that one is plainly good.
What a buyer would ask 2
- One director on the registerA buyer's first question about a company run by one person is what happens to it if that person stops. It is usually the first thing priced.
- No website on file against the companyThe first thing anyone does with a company number is look for the business behind it. Finding nothing is its own answer.
What a buyer would like 2
- 25 years of trading on fileLongevity is the cheapest evidence there is that the business is not one contract.
- Sales per employee better than three quarters of your tradeYours is 1,153,431 against 268,200 for the middle of 1,029 comparable companies.
What the register says
Owners
Nobody recorded with significant control.
Directors
- 52since 2023
| Year to | Filed | Turnover | Staff | Cash |
|---|---|---|---|---|
| 2025-12-31 | 2026-09-10 | £18M | 16 | £1.4M |
| 2023-12-31 | — | £19M | 15 | £735k |
| 2022-12-31 | — | £16M | 15 | £415k |
| 2021-12-31 | — | not filed | 14 | £774k |
A rough bracket, and why it is only that
0.4–0.9× sales£7.4M£17M
The turnover range is fitted on UK companies that did file one. The multiple is a published sector average from Dutch mid-market deals, not from your own numbers and not from your own market. Treat this as the opening bracket of a conversation, not a valuation.